Innovation and care

Radiology and cancer: making way for technologies that enable us to ‘see more to understand better’

The new generation of computed tomography makes it easier to distinguish clinically significant findings from those with no pathological significance

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

Photon-counting computed tomography promises to expand the information available to radiologists, offering high spatial resolution and spectral analysis. In oncology, this capability could enable more precise characterisation of findings and tissues throughout diagnostic pathways involving repeated scans. This new opportunity also presents a training challenge: to bring radiologists, trainee doctors and students up to speed with the capabilities of emerging technologies. It is the ability to see what previously eluded computed tomography (CT) and to better understand what is observed that has sparked interest in the new generation of computed tomography, which was the focus of the symposium organised by GE HealthCare as part of the latest SIRM congress.

Main applications

On the one hand, the new technology makes structures visible that were previously difficult to detect; on the other, it enables specific components – such as iodine, water, fat and crystalline deposits – to be distinguished, thereby improving diagnostic capabilities. This makes it easier to distinguish clinically relevant findings from those with no pathological significance. It is particularly in oncology that this wealth of information could translate into a tangible clinical benefit. Diagnosis, staging, assessment of response to treatment and follow-up mark the stages of a diagnostic journey that can extend over many years. In metastatic patients treated with targeted therapies or immunotherapy, reassessments may even take place every three months. Furthermore, an inconclusive CT scan may be followed by an MRI, PET scan or other investigations to resolve any doubts. The aim is not only to obtain more detailed images, but also potentially to reduce the number of examinations required.
This benefit has yet to be demonstrated across the various clinical indications, but it encourages us to evaluate the technology also in terms of its impact on the entire diagnostic journey. For example: in the liver, treatment-related metabolic changes and steatosis can alter parenchymal attenuation and make it more difficult to identify secondary lesions, currently leading to further investigations using ultrasound or MRI. In the lungs, on the other hand, the higher resolution could help assess peripheral changes and treatment-related toxicity. Bone lesions would be one of the first areas in which to evaluate the technology, as would the brain, a field of particular interest.

Loading...

Limiting exposure to contrast medium

Then there is the issue of repeated exposure to contrast medium. In patients undergoing numerous scans and potentially nephrotoxic treatments, making use of iodine-related sensitivity to information would allow for the development of more targeted protocols, tailoring the quantity and concentration of the contrast medium to the specific diagnostic question. Here too, protocols must be tailored to the clinical indication, distinguishing between vascular studies and interstitial and tissue assessments. Reducing diagnostic uncertainty also means improving the patient’s experience. For those undergoing cancer treatment, every scan (CT, MRI, PET-CT) involves appointments and waiting times, whilst every further investigation prolongs the wait for a result. But having more information is not enough: one must know how to interpret it.

Spectral images can make certain findings easier to recognise, even under the conditions of fatigue that can accompany long reporting sessions. Experience gained with spectral imaging has already shown, in a study on peritoneal carcinomatosis, a reduction in interpretative differences between readers with varying levels of experience. A greater wealth of information can therefore facilitate more intuitive and reproducible readings. When a technology makes visible what was previously invisible, the challenge is not merely to produce more detail, but to learn to recognise it, give it meaning and understand what impact it may have on the patient.

* Professor of Radiodiagnostics at the Department of Medical, Surgical and Neuroscience Sciences – University of Siena

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti